215 related articles for article (PubMed ID: 29535536)
1. Response to crizotinib in a non-small-cell lung cancer patient harboring an
Aguado C; Gil MD; Yeste Z; Giménez-Capitán A; Teixidó C; Karachaliou N; Viteri S; Rosell R; Molina-Vila MA
Onco Targets Ther; 2018; 11():1117-1120. PubMed ID: 29535536
[TBL] [Abstract][Full Text] [Related]
2. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
4. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
5. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
Robesova B; Bajerova M; Hausnerova J; Skrickova J; Tomiskova M; Dvorakova D
Lung Cancer; 2015 Mar; 87(3):318-20. PubMed ID: 25601488
[TBL] [Abstract][Full Text] [Related]
6. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
Doval D; Prabhash K; Patil S; Chaturvedi H; Goswami C; Vaid A; Desai S; Dutt S; Veldore V; Jambhekar N; Mehta A; Hazarika D; Azam S; Gawande S; Gupta S
Onco Targets Ther; 2015; 8():117-23. PubMed ID: 25609979
[TBL] [Abstract][Full Text] [Related]
7. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
Xu X; Liu D; Wen J; Chen J; Fan M
Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
[TBL] [Abstract][Full Text] [Related]
8. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
9. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
10. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
11. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
12. Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
Zhang L; Li Y; Zhang S; Gao C; Nie K; Ji Y
Cancer Biol Med; 2018 May; 15(2):178-181. PubMed ID: 29951342
[TBL] [Abstract][Full Text] [Related]
13. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
14. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
15. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
16.
Ren W; Zhang BO; Ma J; Li W; Lan J; Men H; Zhang Q
Oncol Lett; 2015 Dec; 10(6):3385-3392. PubMed ID: 26788139
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
18. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
Guo Y; Ma J; Lyu X; Liu H; Wei B; Zhao J; Fu S; Ding L; Zhang J
BMC Cancer; 2014 Nov; 14():834. PubMed ID: 25407901
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
